Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 9/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | AGXT | P21549 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439093 | 0.98 | IDO1 (1.00) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL2351746 | 0.82 | IDO1 (0.72) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL37463 | 0.81 | IDO1 (0.70) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL8062311 | 0.81 | IDO1 (0.70) | IDO1LOXL2AKR1C3CA12CA1 | |
| Hydrochloric Acid SCHEMBL5528680 | 0.80 | IDO1 (0.67) | IDO1LOXL2AGXTCYP3A4TSHR | |
| SCHEMBL28381661 | 0.78 | IDO1 (0.67) | IDO1LOXL2AKR1C3CA12CA1 | |
| Hydrochloric Acid SCHEMBL5529280 | 0.78 | IDO1 (0.64) | IDO1AGXTCYP3A4TSHR | |
| SCHEMBL10546903 | 0.78 | IDO1 (0.65) | IDO1LOXL2AKR1C3RAB9A | |
| SCHEMBL23091915 | 0.78 | IDO1 (0.66) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL535425 | 0.78 | IDO1 (0.66) | IDO1LOXL2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674881-B2 | Convergent synthesis of proteins by kinetically controlled ligation | THE UNIVERSITY OF CHICAGO (US) | 2010-03-09 | — | — | US | claimed |
| US-20070082378-A1 | Convergent synthesis of proteins by kinetically controlled ligation | UNIVERSITY OF CHICAGO (US) | 2007-04-12 | — | — | US | claimed |
| EP-4443155-B1 | ENCAPSULATED PRE-ANALYTIC WORKFLOWS FOR FLOW-THROUGH DEVICES, LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRIC ANALYSIS | WATERS TECHNOLOGIES CORP (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12487210-B2 | Encapsulated pre-analytic workflows for flow-through devices, liquid chromatography and mass spectrometric analysis | WATERS TECHNOLOGIES CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3491374-B1 | ENCAPSULATED PRE-ANALYTIC WORKFLOW REAGENTS FOR FLOW-THROUGH DEVICES, LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRIC ANALYSIS | WATERS TECHNOLOGIES CORP (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4443155-A2 | ENCAPSULATED PRE-ANALYTIC WORKFLOWS FOR FLOW-THROUGH DEVICES, LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRIC ANALYSIS | Waters Technologies Corporation (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | PFIZER INC. (US) | 2023-11-02 | — | — | US | disclosed |
| CN-115950970-A | HPLC detection method for ketose in aldose | 唐传生物科技（厦门）有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-115932076-A | Method for detecting ketose in aldose | 唐传生物科技（厦门）有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20220252553-A1 | ENCAPSULATED PRE-ANALYTIC WORKFLOWS FOR FLOW-THROUGH DEVICES, LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRIC ANALYSIS | WATERS TECHNOLIGIES CORPORATION (US) | 2022-08-11 | — | — | US | disclosed |
| US-11280766-B2 | Encapsulated pre-analytic workflows for flow-through devices, liquid chromatography and mass spectrometric analysis | WATERS TECHNOLOGIES CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-5403860-A | Octahydronaphthalene oxime compounds for cholesterol synthesis inhibition | SANKYO COMPANY, LIMITED (JP) | 1995-04-04 | — | — | US | disclosed |
| EP-0307225-B1 | Macrolide compounds | AMERICAN CYANAMID CO (US) | 1994-08-24 | — | — | EP | disclosed |
| EP-0314435-B1 | OCTAHYDRONAPHTHALENE OXIME DERIVATIVES FOR CHOLESTEROL SYNTHESIS INHIBITION, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | Sankyo Company Limited (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-5192777-A | Antibiotics | AMERICAN CYANAMID COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| US-5032581-A | Bactericides, antibiotics | ADIR ET CIE (FR) | 1991-07-16 | — | — | US | disclosed |
| US-4997848-A | Enzyme inhibitors | SANKYO COMPANY, LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| US-4918058-A | Macrolide compounds | ADIR ET CIE (FR) | 1990-04-17 | — | — | US | disclosed |
| EP-0314435-A2 | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them | Sankyo Company Limited (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0307225-A2 | Macrolide compounds | AMERICAN CYANAMID COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082378-A1 | Convergent synthesis of proteins by kinetically controlled ligation | NPEPPS, PTMS, QPCTL | CA2 2739/4885IDO1 4081/4885LOXL2 3111/4885 |
| US-20230346903-A1 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | SIGLEC7, SIGLEC9, FCGR3B | CA2 808/4885IDO1 1444/4885LOXL2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.